Octocog Alfa drug aliquots can be used for in vitro or in vivo experiments. Several other reference drugs are also available.
The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed reference drug.
Find and order your therapeutic molecules through smart filters
Up to 10 batches of original drugs for examining batch-to-batch variations
Up to 80% less compared to the original pharmaceutical price
Shipment within days worldwide according to GDP-standards
Up to 80% less compared to the original pharmaceutical price
| Drug name | Advate® |
| INN | Octocog Alffa |
| API type | Octocog alfa (human coagulation factor VIII (rDNA)) is a purified protein that has 2332 amino acids. It is produced by recombinant DNA technology in Chinese hamster ovary (CHO) cells. Prepared without the addition of any (exogenous) human- or animal-derived protein in the cell culture process, purification or final formulation. |
| Pharmacotherapeutic group | Antihemorrhagics, blood coagulation factor VIII |
| ATC code | B02BD02 |
| Target of antibody | TNF alpha |
| General function | Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Octocog Alfa is indicated in all age groups. |
| Short description | |
| Pharmacodynamic properties (Mechanism of action; Source EMA document) | When infused into a haemophilia patient, octocog alfa binds to endogenous von Willebrand Factor in the patient’s circulation. Activated factor VIII acts as a Cofactor for activated Factor IX, accelerating the conversion of Factor X to activated Factor X. Activated Factor X converts prothrombin to thrombin. Thrombin then converts fibrinogen into fibrin and a clot can be formed. Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII activity and results in profuse bleeding into joints, muscles or internal organs, either spontaneously or as a result of accidental or surgical trauma. The plasma levels of factor VIII are increased by replacement therapy, thereby enabling a temporary correction of the factor VIII deficiency and correction of the bleeding tendency. |
| Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document) | |
| Original license holder | Takeda Manufacturing Austria AG Industriestrasse 67 A-1221 Vienna Austria |
| Marketing authorisation numbers | EU/1/03/271/001 |
| Marketing authorisation holder | Takeda Manufacturing Austria AG Industriestrasse 67 A-1221 Vienna Austria |
| Name of the manufacturer of the biological active substance | Baxalta Manufacturing Sàrl Route de Pierre-à-Bot 111 CH-2000 Neuchâtel Switzerland Baxalta Manufacturing SARL Singapore Branch 2A Woodlands Industrial Park D Street 2 Singapore 737779 Singapore |
| Name and address of the manufacturer(s) responsible for batch release | Baxalta Belgium Manufacturing SA Boulevard René Branquart 80 B-7860 Lessines Belgium |
| Max shelf life | 2 years |
| Storage conditions | 2°C – 8°C |
| List of excipients | Powder: Mannitol, Sodium chloride, Histidine, Trehalose, Calcium chloride, Trometamol, Polysorbate 80, Glutathione (reduced) Solvent: Sterilised water for injections |
Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.
Evidentic GmbH
Am Mühlenberg 10
14476 Potsdam | Germany
